Genitourinary Cancers | Specialty

Government Come to Call? How to Protect Your Practice

November 25th 2014

Urologists hear quite a bit about risk from the legislative and regulatory angles.

Dr. Oh Discusses Updates in Bladder Cancer Treatment

November 24th 2014

William K. Oh, MD, Chief of the Division of Hematology and Medical Oncology, the Tisch Cancer Institute at Mount Sinai Medical Center, discusses recent updates in bladder cancer treatment.

Pre-Chemo Abiraterone Extends Survival in CRPC

November 21st 2014

ADT With GnRH Antagonists in Prostate Cancer

November 21st 2014

Upcoming Advances for GU Cancers

November 21st 2014

Latest News & Insight: November 20, 2014

November 21st 2014

LUGPA Meeting Will Offer Insights Into Urology Practice Management

October 27th 2014

From a limited first meeting in the late 1990s that included the leaders of a dozen large group practices, LUGPA has grown so much that its annual meeting this November will include up to 550 physicians and 200 administrators, filling the organization's usual Chicago venue to capacity and necessitating a move to a larger space next year.

Novel Drugs Are Being Studied in GU Cancers

October 25th 2014

A round-up of new drugs that are being investigated as treatments for genitourinary cancers.

ICD-10 and Urologic Oncology: A Disappointing Combination

October 24th 2014

The 12-month countdown to the adoption of ICD-10 has begun. ICD-10 represents the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (usually referred to as "ICD"), now overseen by the World Health Organization (WHO).

How Test Reimbursement Decisions Are Made: A Leader of Medicare's MolDX Program Discusses Evaluation Process

October 21st 2014

Despite the promise associated with biomarker-based tools as a means of helping to guide cancer diagnosis and treatment, there is a potential stumbling block: insurance reimbursement.

Petrylak Anticipates Bright Future for PD-L1 Inhibitors in Bladder Cancer

October 9th 2014

Checkpoint inhibitors targeting the PD-1 receptor and its ligand, PD-L1, are showing efficacy in early-phase clinical trials in urothelial bladder cancer, generating the promise of new therapies for a disease that has not had a significant treatment advance in 30 years.

Commercial Tests Offer Guidance in Bladder, Renal, Testicular Cancers

October 7th 2014

While biomarker-based tools designed to guide the diagnosis and treatment of prostate cancer are emerging at an extraordinarily rapid rate, they are not exploding in the same practice-changing way in all genitourinary cancers.

Targeting Src Adds No Benefit in VEGF-Resistant Metastatic Renal Cell Carcinoma

October 6th 2014

Adding saracatinib to vascular endothelial growth factor (VEGF)-targeted therapy did not improve response rates or overall survival while adding to toxicity in VEGF-resistant metastatic renal cell carcinoma

Durable Responses Observed with Nivolumab in Previously Treated mRCC

September 30th 2014

Durable responses were obtained with the immune checkpoint inhibitor nivolumab, with a manageable safety profile, in a phase II dose-ranging trial conducted in patients with previously treated metastatic renal cell carcinoma (mRCC).

Dr. Motzer on a Phase II Trial of Nivolumab for mRCC

September 30th 2014

Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of a phase II study of nivolumab for the treatment of patients with clear cell metastatic renal cell carcinoma.

Robotic Prostatectomy Rises, and So Do Costs: Study Tracks Patterns

September 17th 2014

Robotic-assisted radical prostatectomy (RARP) was widely adopted in the United States between 2003 and 2010, mainly among high-volume surgeons.

A Call to Arms

September 8th 2014

The year was 1989, and I was one year away from finishing six years of residency in general surgery and urology.

Urology Clinics Must Lead Way in Preventing Workplace Violence

August 29th 2014

It took just a minute and a half for a disgruntled patient to leave his deadly mark on a Nevada urology clinic, irreversibly changing the lives of everyone inside.

Molecularly Targeted Therapy and Immunotherapy: The Next Frontier in Metastatic Bladder Cancer

August 27th 2014

A major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.

Dr. Parsons Discusses the Link Between Exercise and Bladder Cancer Risk

August 25th 2014

J. Kellogg Parsons, MD, associate professor of surgery (urology), University of California, San Diego, discusses modifiable lifestyle factors associated with bladder cancer.